NASDAQ:KURA

Kura Oncology Stock Forecast, Price & News

$33.69

-0.41 (-1.20 %)

(As of 12/2/2020 04:30 PM ET)

Add

Compare

Today's Range

$33.09

Now: $33.69▼

$34.37

50-Day Range

$29.00

MA: $34.81▼

$40.07

52-Week Range

$6.35

Now: $33.69▼

$40.62

Volume687,846 shs

Average Volume582,264 shs

Market Capitalization$1.91 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.31

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank^™

2.5 Analyst's Opinion

Consensus Rating
Kura Oncology has received a consensus rating of Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.33, Kura Oncology has a forecasted upside of 1.8% from its current price of $33.72.
Amount of Analyst Coverage
Kura Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Kura Oncology has received 351 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Kura Oncology has received 311 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Kura Oncology has received 53.02% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote “Outperform” if you believe KURA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Kura Oncology does not currently pay a dividend.
Dividend Growth
Kura Oncology does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,857,539.00 in company stock.
Percentage Held by Insiders
Only 11.00% of the stock of Kura Oncology is held by insiders.
Percentage Held by Institutions
91.26% of the stock of Kura Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Kura Oncology are expected to decrease in the coming year, from ($1.71) to ($2.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kura Oncology is -20.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kura Oncology is -20.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kura Oncology has a P/B Ratio of 6.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.36 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KURA

Previous Symbol

CUSIPN/A

CIK1422143

Webwww.kuraoncology.com

Phone858-500-8800

Employees71

Debt

Debt-to-Equity Ratio0.02

Current Ratio15.15

Quick Ratio15.15

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.40 per share

Price / Book6.24

Profitability

EPS (Most Recent Fiscal Year)($1.51)

Net Income$-63,140,000.00

Net MarginsN/A

Return on Equity-30.96%

Return on Assets-28.02%

Miscellaneous

Outstanding Shares56,708,000

Market Cap$1.91 billion

Next Earnings Date2/23/2021 (Estimated)

OptionableOptionable

$33.69

-0.41 (-1.20 %)

(As of 12/2/2020 04:30 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

How has Kura Oncology's stock been impacted by COVID-19?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KURA shares have increased by 250.8% and is now trading at $33.85.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Kura Oncology?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kura Oncology or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Kura Oncology?

Wall Street analysts have given Kura Oncology a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kura Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Kura Oncology.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.03.
View Kura Oncology's earnings history.

What price target have analysts set for KURA?

10 brokers have issued 12-month target prices for Kura Oncology's stock. Their forecasts range from $24.00 to $43.00. On average, they expect Kura Oncology's stock price to reach $34.33 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price.
View analysts' price targets for Kura Oncology.

Are investors shorting Kura Oncology?

Kura Oncology saw a increase in short interest in November. As of November 15th, there was short interest totaling 4,330,000 shares, an increase of 25.9% from the October 31st total of 3,440,000 shares. Based on an average trading volume of 724,000 shares, the short-interest ratio is currently 6.0 days.
View Kura Oncology's Short Interest.

Who are some of Kura Oncology's key competitors?

Some companies that are related to Kura Oncology include Ultragenyx Pharmaceutical (RARE), Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), Perrigo (PRGO), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), BridgeBio Pharma (BBIO), Amicus Therapeutics (FOLD), United Therapeutics (UTHR), Blueprint Medicines (BPMC), Turning Point Therapeutics (TPTX), Allakos (ALLK), Biohaven Pharmaceutical (BHVN), Evotec (EVTCY) and Reata Pharmaceuticals (RETA).
View all competitors.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:

Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 51, Pay $908.26k)
Dr. Marc Grasso, CFO & Chief Bus. Officer (Age 47, Pay $630.86k)
Ms. Kathleen Ford, Chief Operating Officer (Age 73, Pay $492.28k)
Mr. James E. Basta J.D., Esq., Chief Legal Officer, Chief Compliance Officer & Corp. Sec. (Age 54, Pay $168.94k)
Mr. Pete De Spain, VP of Investor Relations & Corp. Communications
Dr. Blake Tomkinson M.B.A., Ph.D., Head of Portfolio Strategy & Program Management
Ms. Kirsten Flowers, Chief Commercial Officer (Age 45)
Dr. Roger Bakale Ph.D., VP and Head of CMC, Clinical & Commercial Manufacturing
Dr. Stephen Dale M.D., Chief Medical Officer

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.79%), State Street Corp (3.08%), Victory Capital Management Inc. (3.03%), Boxer Capital LLC (1.85%), Candriam Luxembourg S.C.A. (0.96%) and Polar Capital LLP (0.88%). Company insiders that own Kura Oncology stock include Antonio Gualberto, Ecor1 Capital Fund Qualified,, Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology.

Which major investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Victory Capital Management Inc., Sphera Funds Management LTD., Alethea Capital Management LLC, AXA S.A., Squarepoint Ops LLC, State of New Jersey Common Pension Fund D, and J. Goldman & Co LP. Company insiders that have sold Kura Oncology company stock in the last year include Kathleen Ford, Marc Grasso, and Troy Edward Wilson.
View insider buying and selling activity for Kura Oncology.

Which major investors are buying Kura Oncology stock?

KURA stock was bought by a variety of institutional investors in the last quarter, including Polar Capital LLP, Polar Capital LLP, Assenagon Asset Management S.A., Candriam Luxembourg S.C.A., Federated Hermes Inc., Boxer Capital LLC, DekaBank Deutsche Girozentrale, and Voloridge Investment Management LLC.
View insider buying and selling activity for Kura Oncology.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $33.85.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $1.92 billion. The company earns $-63,140,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Kura Oncology employs 71 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at 858-500-8800 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings